藥碼
TAT01
藥名
Ceftazidime 針 2 g/Vial
英文商品名
Tatumcef 針 2 g/Vial
中文商品名
祐坦賜褔乾粉注射劑
螢幕名
Tatumcef 針 2 g/Vial
劑型
Inj
規格
Inj 2gm/Vial (2.3 mEq of Na/g).
成分
藥理分類
Cephalosporins
健保碼
AC38949212
ATC碼
適應症
Cephalosporins類抗生素 (三四代)
Bloodstream infection (gram-negative bacteremia): caused by P. aeruginosa, Klebsiella spp., H. influenzae, E. coli, Serratia spp., S. pneumoniae, and S. aureus
Bone and joint infections: caused by P. aeruginosa, Klebsiella spp., Enterobacter spp., and S. aureus
CNS infections: caused by H. influenzae and Neisseria meningitidis; also been used in cases of meningitis due to P. aeruginosa and S. pneumoniae
Empiric therapy in immunocompromised patients: Empiric treatment of infections in immunocompromised patients
Gynecologic infections: Treatment of endometritis, pelvic cellulitis, and other infections of the female genital tract caused by E. coli
Intra-abdominal infection, health care-associated or high-risk community-acquired infection: caused by E. coli, Klebsiella spp., S. aureus
Lower respiratory tract infections: including pneumonia; caused by P. aeruginosa, H. influenzae, Enterobacter spp., Proteus mirabilis. E. coli. Serratia spp., Citrobacter spp., S. pneumoniae, and S. aureus
Skin and soft tissue infections: caused by P. aeruginosa, Klebsiella spp., E. coli, Proteus spp., Enterobacter spp., Serratia spp., S. aureus, and Streptococcus pyogenes
Urinary tract infection: caused by P. aeruginosa, Enterobacter spp., Proteus spp., Klebsiella spp., and E. coli
Bloodstream infection (gram-negative bacteremia): caused by P. aeruginosa, Klebsiella spp., H. influenzae, E. coli, Serratia spp., S. pneumoniae, and S. aureus
Bone and joint infections: caused by P. aeruginosa, Klebsiella spp., Enterobacter spp., and S. aureus
Empiric therapy in immunocompromised patients: Empiric treatment of infections in immunocompromised patients
Gynecologic infections: Treatment of endometritis, pelvic cellulitis, and other infections of the female genital tract caused by E. coli
Intra-abdominal infection, health care-associated or high-risk community-acquired infection: caused by E. coli, Klebsiella spp., S. aureus
Lower respiratory tract infections: including pneumonia; caused by P. aeruginosa, H. influenzae, Enterobacter spp., Proteus mirabilis. E. coli. Serratia spp., Citrobacter spp., S. pneumoniae, and S. aureus
Skin and soft tissue infections: caused by P. aeruginosa, Klebsiella spp., E. coli, Proteus spp., Enterobacter spp., Serratia spp., S. aureus, and Streptococcus pyogenes
Urinary tract infection: caused by P. aeruginosa, Enterobacter spp., Proteus spp., Klebsiella spp., and E. coli
藥理
Antibiotic, Cephalosporin (Third Generation)
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic which inhibits enzymes responsible for cell-wall synthesis. It is bactericidal against a wide range of gram-negative and gram-positive organisms but is highly stable to clinically important plasmid and chromosomal beta-lactamases produced by these organisms.
Ceftazidime is a semisynthetic, broad-spectrum, beta-lactam antibiotic which inhibits enzymes responsible for cell-wall synthesis. It is bactericidal against a wide range of gram-negative and gram-positive organisms but is highly stable to clinically important plasmid and chromosomal beta-lactamases produced by these organisms.
藥動學
Widely distributed throughout the body including bone, bile, skin, CSF (higher concentrations achieved when meninges are inflamed), endometrium, heart, pleural and lymphatic fluids; approximately 80% to 90% unchanged excreted in urine over a 24-hour period. Dialyzable: yes (hemodialysis); yes (peritoneal dialysis).
禁忌症
Patients with known hypersensitivity to cephalosporins.
懷孕分類
B
哺乳分類
In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea.
Although the manufacturer recommends that caution be exercised when administering ceftazidime to nursing women, ceftazidime is considered compatible with breastfeeding when used in usual recommended doses.
Although the manufacturer recommends that caution be exercised when administering ceftazidime to nursing women, ceftazidime is considered compatible with breastfeeding when used in usual recommended doses.
副作用
Eosinophilia, positive direct Coombs test, thrombocythemia; Increased serum ALT and AST, increased serum alkaline phosphatase ; Increased lactate dehydrogenase, increased gamma-glutamyl transferase; Allergic reaction; Phlebitis
劑量和給藥方法
Usual dosage:
1. Traditional intermittent infusion method:
(IV) 1-2g Q8H infused over 30 minutes; for treatment of very severe life-threatening infections, 2g Q8H
2. Extended infusion method (off-label method):
(IV) 2 g Q8H infused over 3 to 4 hours; may give first dose over 30 minutes, especially when rapid attainment of therapeutic drug concentrations is desired (eg, sepsis)
3. Continuous infusion method (off-label method):
(IV) 6 g infused over 24 hours; may give first dose of 2 g over 30 minutes, especially when rapid attainment of therapeutic drug concentrations is desired (eg, sepsis)
1. Traditional intermittent infusion method:
(IV) 1-2g Q8H infused over 30 minutes; for treatment of very severe life-threatening infections, 2g Q8H
2. Extended infusion method (off-label method):
(IV) 2 g Q8H infused over 3 to 4 hours; may give first dose over 30 minutes, especially when rapid attainment of therapeutic drug concentrations is desired (eg, sepsis)
3. Continuous infusion method (off-label method):
(IV) 6 g infused over 24 hours; may give first dose of 2 g over 30 minutes, especially when rapid attainment of therapeutic drug concentrations is desired (eg, sepsis)
小兒調整劑量
General dosing, susceptible infection: IM, IV
1. Non-Pseudomonas spp. infections: 90-150 mg/kg/day divided every 8 hours; maximum 6 g/day
2. Pseudomonas spp. infections:
(1) Mild to moderate infections: 90-150 mg/kg/day divided Q8H; maximum 6 g/day
(2) Severe infections: 200-300 mg/kg/day divided Q8H; maximum 12 g/day
1. Non-Pseudomonas spp. infections: 90-150 mg/kg/day divided every 8 hours; maximum 6 g/day
2. Pseudomonas spp. infections:
(1) Mild to moderate infections: 90-150 mg/kg/day divided Q8H; maximum 6 g/day
(2) Severe infections: 200-300 mg/kg/day divided Q8H; maximum 12 g/day
腎功能調整劑量
If the usual recommended dose is 1g Q8H:
1. CrCl >50 mL/min: No dose adjustment necessary
2. CrCl 31-50 mL/min: 1g Q12H
3. CrCl 16-30 mL/min: 1g Q24H
4. CrCl ≤15 mL/min: 500mg Q24H
If the usual recommended dose is 2g Q8H:
1. CrCl >50 mL/min: No dose adjustment necessary
2. CrCl 31-50 mL/min: 2g Q12H
3. CrCl 16-30 mL/min: 2g Q24H
4. CrCl ≤15 mL/min: 1g Q24H
Hemodialysis, intermittent (thrice weekly):
Dialyzable (55% to 88% utilizing low-flux filters)
(IV) 500 mg to 1 g every 24 hours; administer after hemodialysis on dialysis days
1. CrCl >50 mL/min: No dose adjustment necessary
2. CrCl 31-50 mL/min: 1g Q12H
3. CrCl 16-30 mL/min: 1g Q24H
4. CrCl ≤15 mL/min: 500mg Q24H
If the usual recommended dose is 2g Q8H:
1. CrCl >50 mL/min: No dose adjustment necessary
2. CrCl 31-50 mL/min: 2g Q12H
3. CrCl 16-30 mL/min: 2g Q24H
4. CrCl ≤15 mL/min: 1g Q24H
Hemodialysis, intermittent (thrice weekly):
Dialyzable (55% to 88% utilizing low-flux filters)
(IV) 500 mg to 1 g every 24 hours; administer after hemodialysis on dialysis days
肝功能調整劑量
No dosage adjustment necessary.
安定性
以注射用水或可配合之輸注液調製成之溶液可於室溫中貯存18小時，或於冰箱中存放7天。
注射給藥指引
給藥途徑
extended IVD (靜脈滴注)/IVF (靜脈輸注) (仿單、Handbook)
靜脈輸注液
再生溶液：SWFI (仿單)。稀釋溶液：NS、D5W、LR (Handbook)。
每瓶稀釋液體積
IV (靜脈注射)：加入10mL稀釋液；IVD (靜脈滴注)：加入50mL稀釋液 (調配供靜脈點滴用之溶液時，稀釋液應分兩次加入) (仿單)
注射濃度
-
給藥速率
15-30分鐘 (Handbook)
安定性
以注射用水或可配合之輸注液調製成之溶液可於室溫中貯存18小時，或於冰箱中存放7天。
注意事項
此藥品以天歸整：至多保存一天，每日給藥。
* NS：0.9%生理食鹽水； D5W：5%葡萄糖水； LR：乳酸林格氏液； 1/2NS：0.45%生理食鹽水； SWFI：注射用水
* NS：0.9%生理食鹽水； D5W：5%葡萄糖水； LR：乳酸林格氏液； 1/2NS：0.45%生理食鹽水； SWFI：注射用水
藥袋資訊
臨床用途
抗生素
主要副作用
腹瀉、腸胃不適、胃痛等
泡製方法
儲存方式
請置於 15-30℃ 乾燥處儲存
注意事項
其他說明
藥局 b2 | 小庫 A | 藥庫 注E22
藥品外觀
顏色
形狀
剝痕
標記1
標記2
其他
健保藥價
126
自費價
167.58
仿單
資料庫
健保給付規定
## 資料使用與著作權聲明 本網站提供之藥品資訊，主要供醫療照護、藥事服務、衛教及一般資訊查詢使用。網站內容包含藥品名稱、成分、劑型、規格、適應症、使用方式、劑量、注意事項及其他相關資訊，實際內容依各藥品資料來源及本院資料建置情形而定。 一、醫療使用聲明 本網站所提供之藥品資訊僅供參考，不應單獨作為診斷、治療、處方調整、停藥或自行用藥之依據。 藥品之實際適應症、使用方法、使用劑量、使用頻率、療程及相關注意事項，應依個別病人之病情、年齡、肝腎功能、合併用藥及其他臨床狀況，由醫師或其他具資格之醫療專業人員進行專業判斷。 病人實際使用藥品時，請以醫師處方、藥袋標示及醫療專業人員之指示為依歸。請勿僅依本網站資訊自行增加、減少、停止或改變藥品使用方式及劑量。 如網站資訊與醫師處方、藥袋標示或醫療專業人員指示有所不同，應優先依醫師處方及醫療專業人員之個別指示使用。 二、資料來源與更新 本網站藥品資訊參考藥品資訊資料庫、主管機關核准之藥品仿單、藥品許可證資料、藥品製造或供應廠商提供之資料、本院藥品管理資料，以及其他經評估之專業資訊來源。 藥品資訊可能因主管機關核准內容、藥品許可證、仿單、供應狀況或臨床建議更新而有所變動，本網站將依實際作業情形進行維護與更新。 如需確認最新藥品核准資訊，應以主管機關公告、最新版藥品仿單及醫療專業人員判斷為準。 三、資料使用範圍 本網站內容可供個人查詢、醫療照護、衛教及非商業性學習使用。 使用者引用或轉載本網站內容時，應註明資料來源，並保留原有內容之完整性及必要之醫療警語，不得任意變更、變更原意或其他可能造成錯誤醫療理解之方式使用。 未經授權，不得將本網站內容大量重製、建立資料庫、進行商業性再利用，或以其他方式侵害相關著作權或其他權利。 四、著作權及第三方資料 本網站由本院自行製作之文字、編排、圖表、圖示及其他內容，其著作權或相關權利依著作權法及其他相關法令受到保護。 網站中引用之藥品仿單、藥品圖片、商標、產品名稱、主管機關資料或其他第三方資料，其著作權、商標權或其他相關權利仍歸原權利人所有。 本網站對第三方資料之使用，以醫療資訊提供、教育、研究或其他合法使用目的為原則，相關權利仍應依原資料來源及相關法令辦理。 五、責任範圍 本網站致力於維持資料之正確性與完整性，但藥品資訊可能隨核准事項、臨床資訊及供應狀況變更。 使用者因個別疾病、用藥或治療問題需要醫療判斷時，應洽詢醫師、藥師或其他適當之醫療專業人員。 本網站提供之一般性藥品資訊，無法取代醫療專業人員依個別病人狀況所作之醫療評估、處方及用藥指導。 六、聲明內容之調整 本院得依相關法令、資料來源、網站功能及實際作業需要，適時修訂本聲明內容。